Monogram Orthopaedics, Inc.
MGRM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.31 | 0.24 | -0.09 |
| FCF Yield | 2.41% | -2.39% | -3.93% | -5.30% |
| EV / EBITDA | -29.34 | -28.08 | -22.03 | -13.74 |
| Quality | ||||
| ROIC | -34.46% | -24.41% | -17.69% | -28.68% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | -0.43 | 0.73 | 0.71 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 752,034.95% | 752,034.95% | 752,034.95% | 487.50% |
| Free Cash Flow Growth | 200.00% | 18.67% | 32.90% | -60.08% |
| Safety | ||||
| Net Debt / EBITDA | 4.08 | 4.01 | 5.44 | 3.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.74 | 0.37 |
| Cash Conversion Cycle | -795.50 | -989.17 | -374.82 | -1,035.06 |